Previous 10 | Next 10 |
NEWARK, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that r...
NEWARK, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p...
Summary Shares have fallen by nearly 40% since 2021 IPO. Oral MDM2 inhibitor milademetan potentially has an efficient path to market via pivotal study in WD/DD LPS (rare cancer). Basket studies in MDM2-amplified tumors as well as patients with CDKN2A loss exponentially increase mark...
Summary Rain Oncology is a late-stage oncology company. Their lead product, milademetan, is an oral inhibitor of the MDM2-p53. In the past, MDM2 inhibitors have been associated with severe hematologic events. In an early study, milademetan showed a median PFS of 7.2 months in patients w...
NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Rain Oncology (NASDAQ: RAIN), the company is updating their presentation date and time to Thursday, February 9, 2023, at 3:55 p.m. ET. Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-sta...
Roth Capital has resumed coverage of Rain Oncology ( NASDAQ: RAIN ) with a buy rating saying that the company's lead candidate, milademetan for liposarcoma, has a positive risk/reward setup in advance of a Q1 data readout The firm has a price target of $21 (~117% upside based on Monda...
NEWARK, Calif., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p...
– Intermittent dosing of milademetan, an inhibitor of the p53-MDM2 complex, potentially exhibits an avenue to address historical issues with cytopenias with this class of compounds– – Phase 1 data in advanced dedifferentiated liposarcoma provides foundation for the ...
Biotechnology company Rain Therapeutics ( NASDAQ: RAIN ) is set to change its name to Rain Oncology, effective Dec. 30. The name change intends to better reflect the company's focus on addressing unmet needs for cancer patients through precision oncology. The company will also hav...
NEWARK, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (“Rain”) (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 com...
News, Short Squeeze, Breakout and More Instantly...
Rain Therapeutics Inc. Company Name:
RAIN Stock Symbol:
NASDAQ Market:
Rain Therapeutics Inc. Website:
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights Pathos AI, Inc. (“Pathos”) today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to acquire ...
NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. (“Pathos”) will acquire Rain for $1.16 in cash per share plus a non-tradeable conting...